ACHE and early-onset autosomal dominant Alzheimer disease: Among all the AAs, the reversible acetylcholinesterase inhibitor galanthamine is yet the only one to be approved for medicinal purposes to treat early symptoms of Alzheimer’s disease in humans [6].